PHI with Fibroplastic endocarditis
How does this condition affect your private health insurance?
Endocarditis fibroplastica, also known as Loeffler's endocarditis, is a rare and severe form of restrictive cardiomyopathy, most frequently associated with hypereosinophilic syndrome. It is characterized by progressive fibrous thickening of the endocardium, particularly in the ventricular apices and inflow tracts, which significantly impairs diastolic filling and leads to restrictive heart failure. This fibrotic process can involve the chordae tendineae and papillary muscles, causing severe valvular regurgitation, commonly affecting the mitral and tricuspid valves. Patients present with symptoms of heart failure, arrhythmias, and are at high risk for thromboembolic complications. Without timely diagnosis and aggressive treatment, which focuses on managing the underlying eosinophilia and heart failure, the prognosis is poor.
PKV Risk Assessment
However, some specialized PHI providers may insure you with a surcharge of up to 40%.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months, often escalating to acute heart failure symptoms.
Duration of Illness (Lifetime)
Chronic and progressive, often leading to lifelong management or early mortality.
Cost of Treatment (Initial)
High (tens of thousands of USD), involving extensive diagnostics, hospitalization, and initial immunosuppressive/symptomatic therapy.
Cost of Treatment (Lifetime)
Very high (hundreds of thousands to millions of USD), including chronic medication, repeated hospitalizations, potential for cardiac surgery or transplantation.
Mortality Rate
High, 30-50% within 5 years, higher if untreated or in advanced stages due to progressive heart failure.
Risk of Secondary Damages
Very high (e.g., severe heart failure, arrhythmias, thromboembolic events such as stroke, and multi-organ dysfunction).
Probability of Full Recovery
Very low; management focuses on halting progression and symptom control rather than complete reversal of fibrosis.
Underlying Disease Risk
High, most commonly hypereosinophilic syndrome (HES) or other eosinophil-related disorders.